Alpa Laboratories Limited

ALPA.NS · National Stock Exchange of India · INR

56,58INR

+0,65 (+1,16 %)Stand 9. Nov., 9:59

Vortag 55,93

Kennzahlen

Eröffnung
56,20
Vortag
55,93
Tagesspanne
54,60 – 58,25
52 Wochen
46,10 – 92,50
Volumen
27.113
Ø Volumen
16.532
Börsenwert
1,19 Mrd. INR
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
1,0
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-grade medications, encompassing ethical, generic, and over-the-counter varieties, available in diverse forms such as injections, tablets, capsules, eye and ear drops, ointments, creams, and gels. Furthermore, it supplies veterinary pharmaceuticals, including boluses, injections, and intra-mammary infusions. Its extensive product range addresses numerous therapeutic categories, including anti-infectives (covering antibacterials, antibiotics, antifungals, antiprotozoals, and antivirals), pain relievers, anti-inflammatory drugs, cold and cough remedies, cardiovascular treatments, anti-diabetic agents, nutritional supplements, psychotropic medicines, and specialized preparations for skin, ear, and eye care. Alpa Laboratories distributes its goods through a robust network comprising distributors, retail pharmacies, and hospitals. The company also extends its reach internationally, exporting its products to various regions across South and Central America, Africa, Asia, and the CIS countries.

CEO
Mahendra Singh Chawla
Mitarbeitende
457
Hauptsitz
Indore, MP, IN
Sektor
Healthcare
Branche
Drug Manufacturers - Specialty & Generic
Börsengang
6. Aug. 2007

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.